APA (7th ed.) Citation

Melander, S. A., Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2024). Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long‐acting dual amylin and calcitonin receptor agonist improves insulin‐mediated glycaemic control and controls body weight. British Journal of Pharmacology, 181(12), 1829. https://doi.org/10.1111/bph.16329

Chicago Style (17th ed.) Citation

Melander, Simone Anna, Anna Thorsø Larsen, Morten Asser Karsdal, and Kim Henriksen. "Are Insulin Sensitizers the New Strategy to Treat Type 1 Diabetes? A Long‐acting Dual Amylin and Calcitonin Receptor Agonist Improves Insulin‐mediated Glycaemic Control and Controls Body Weight." British Journal of Pharmacology 181, no. 12 (2024): 1829. https://doi.org/10.1111/bph.16329.

MLA (9th ed.) Citation

Melander, Simone Anna, et al. "Are Insulin Sensitizers the New Strategy to Treat Type 1 Diabetes? A Long‐acting Dual Amylin and Calcitonin Receptor Agonist Improves Insulin‐mediated Glycaemic Control and Controls Body Weight." British Journal of Pharmacology, vol. 181, no. 12, 2024, p. 1829, https://doi.org/10.1111/bph.16329.